StoxGlenmark Pharmaceuticals vs Gland Pharma: share price & financials comparison
NSE: GLENMARK vs GLAND · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Gland Pharma at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹74,506 Cr, against ₹55,016 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +74.4%, compared with +43.1% for Glenmark Pharmaceuticals. On valuation, Gland Pharma trades at a lower P/E of 44.5 versus 84.1. Gland Pharma earns a higher return on equity (11.6% vs 7.9%). Glenmark Pharmaceuticals comes out ahead on momentum. Gland Pharma comes out ahead on size, valuation, profitability, growth, financial health and technicals. Across the scored metrics below, Glenmark Pharmaceuticals leads on 3 and Gland Pharma on 14. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Gland Pharma scores 8/10.
| Metric | Glenmark Pharmaceuticals | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹74,506 Cr | ₹55,016 Cr |
| Revenue (latest FY) | ₹16,983 Cr | ₹6,431 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹1,027 Cr |
| Valuation | ||
| P/E | 84.1 | 44.5 |
| P/B | 6.64 | 5.15 |
| Dividend yield | 0.19% | 0.54% |
| Profitability | ||
| Return on equity | 7.9% | 11.6% |
| Net profit margin | 5.6% | 17.5% |
| Operating margin | 20.3% | 27.2% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +23.3% |
| Net profit growth (YoY) | -100.0% | +58.3% |
| Revenue CAGR (multi-year) | +9.2% | +13.2% |
| Financial health | ||
| Debt to equity | 0.08 | 0.02 |
| Momentum | ||
| 1-month return | +16.5% | +7.9% |
| 1-year return | +43.1% | +74.4% |
| 3-year CAGR | +53.9% | +27.0% |
| 5-year CAGR | +37.6% | -1.7% |
| 10-year CAGR | +11.7% | — |
| Distance from 52W high | -1.4% | +0.0% |
| Technicals | ||
| RSI (14) | 85 | 88 |
| Price vs 200-day avg | +17.4% | +42.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Gland Pharma?
Glenmark Pharmaceuticals has a market cap of ₹74,506 Cr and Gland Pharma has a market cap of ₹55,016 Cr as of 13 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Gland Pharma?
Gland Pharma has the lower P/E: Glenmark Pharmaceuticals trades at 84.1 and Gland Pharma at 44.5.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Gland Pharma?
Gland Pharma did better: Glenmark Pharmaceuticals returned +43.1% and Gland Pharma returned +74.4% over one year.
What is the difference between Glenmark Pharmaceuticals and Gland Pharma?
Both are NSE-listed companies in Healthcare. Glenmark Pharmaceuticals is about 1.4 times the size of Gland Pharma by market cap. In the latest financial year Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr and Gland Pharma ₹6,431 Cr. Operating margin is 20.3% for Glenmark Pharmaceuticals and 27.2% for Gland Pharma. Debt to equity is 0.08 for Glenmark Pharmaceuticals and 0.02 for Gland Pharma.
Which is better, Glenmark Pharmaceuticals or Gland Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Glenmark Pharmaceuticals leads on 3 and Gland Pharma on 14. Glenmark Pharmaceuticals is ahead on momentum. Gland Pharma is ahead on size, valuation, profitability, growth, financial health and technicals. On StoxGud's rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Gland Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.